Calcium phosphate cement (CPC) is generally used for bone repair and augmentation. Poloxamers are tri‐block copolymers that are used as surfactants but have applications in drug and antibiotic delivery. However, their biological effects on bone regeneration systems remain unelucidated. Here, we aimed to understand how supplementing the prototype CPC with poloxamer would impact cellular activity and its function as a bone‐grafting material. A novel CPC, modified beta‐tricalcium phosphate (mβ‐TCP) powder, was developed through a planetary ball‐milling process using a beta‐tricalcium phosphate (β‐TCP). The mβ‐TCP dissolves rapidly and accelerates hydroxyapatite precipitation; successfully shortening the cement setting time and enhancing the strength. Furthermore, the addition of poloxamer 407 to mβ‐TCP could reduce the risk of leakage from bone defects and improve fracture toughness while maintaining mechanical properties. In this study, the poloxamer addition effects (0.05 and 0.1 g/mL) on the cellular activities of MC3T3‐E1 cells cultured in vitro were investigated. The cell viability of mβ‐TCP containing poloxamer 407 was similar to that of mβ‐TCP. All specimens showed effective cell attachment and healthy polygonal extension of the cytoplasm firmly attached to hydroxyapatite (HA) crystals. Therefore, even with the addition of poloxamer to mβ‐TCP, it does not have a negative effect to osteoblast growth. These data demonstrated that the addition of poloxamer 407 to mβ‐TCP might be considered a potential therapeutic application for the repair and regeneration of bone defects.